BSECompany Update31 Jul 2026 · 31 Jul 2026, 07:01 pm
Please find attached Company''s officials authorised for the purpose of determining materiality of an event or information and making disclosures to the Stock Exchanges
Glenmark Pharmaceuticals Ltd · 532296
✦ AI Summary
Glenmark Pharmaceuticals Ltd has updated the list of officials authorized to determine materiality of events and make disclosures to stock exchanges, as per Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Glenmark Pharmaceuticals Ltd - 532296 - Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - List Of Officials
Attachments (1)
📄pdf
Download →
89373aea-58e3-4662-b153-9f1ac169e7a4.pdf
View document text
July 31, 2026
To, To,
National Stock Exchange of India Limited, BSE Limited,
“Exchange Plaza”, Corporate Relationship Department,
5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring,
Bandra- Kurla Complex Bandra (East), Mumbai – P.J. Towers, Dalal Street,
400 051 Mumbai – 400 001
Scrip Name: GLENMARK Scrip Code: 532296
ISIN: INE935A01035 ISIN: INE935A01035
Our Reference No. 36/26-27 Our Reference No. 36/26-27
Dear Sir/ Madam,
Sub: Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,
2015 – List of Officials
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”), we would like to inform you
that the Board of Directors of the Company in the meeting held on Friday, July 31, 2026 at 4:00 p.m.
approved the amendments to Policy on Determination of Materiality for Disclosures.
Further, the Company’s officials authorised for the purpose of determining materiality of an event or
information and making disclosures to the stock exchange(s) under the Listing Regulation is as under:
Sr. Name & Designation Contact Details
No. Designation
1. Mr. Glenn Saldanha Chairman & Managing Glenmark Pharmaceuticals Limited
Director
Add.: Glenmark House, B D Sawant Marg,
2. Mrs. Cherylann Executive Director –
Andheri (E), Mumbai 400 099
Pinto Corporate Services
3. Mr. Anurag Mantri Executive Director & Global
Tel No.: 91 22 4018 9999
Chief Financial Officer
4. Ms. Rashmi Company Secretary & Email ID:
Khandelwal Compliance Officer complianceofficer@glenmarkpharma.com
For Glenmark Pharmaceuticals Limited
Rashmi Khandelwal
Company Secretary & Compliance Officer
ACS – 28839
Glenmark Pharmaceuticals Limited
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099
T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E:complianceofficer@glenmarkpharma.com